Foundayo is a once-daily tablet for weight loss, approved by the FDA in April 2026. Its active ingredient is orforglipron, and it is the first GLP-1 medication that is a small molecule rather than a peptide — which is why it can be swallowed with breakfast instead of injected.
The short version
| What it is | A daily tablet for weight management |
| Active ingredient | Orforglipron |
| Maker | Eli Lilly |
| Approved | April 2026, United States |
| Approved for | Adults with obesity, or overweight plus a weight-related condition |
| How it works | Activates the GLP-1 receptor, reducing appetite |
| Typical result | 11.1% mean weight loss at the maximum dose over 72 weeks |
| Self-pay price | From $149 a month |
Why "small molecule" is the whole story
Every GLP-1 drug before it — semaglutide, tirzepatide, liraglutide — is a peptide, a short chain of amino acids. Peptides are what the body uses as hormones, and they are also what the digestive system is built to break down. That is why those drugs are injected: swallow a peptide and the stomach destroys it.
Orforglipron is not a peptide. It is a conventional small molecule, chemically synthesised, of the kind most tablets are made from. It survives the stomach on its own, with no special formulation and no rules about food or water.
Two consequences follow. It can be made at industrial scale in a chemistry plant rather than grown in cell cultures, which is why it is the cheapest branded GLP-1 available. And it is metabolised by liver enzymes the way ordinary drugs are, which gives it drug interactions that injected GLP-1s do not have — set out in Foundayo dosage.
What it does, and how well
Foundayo activates the GLP-1 receptor, the same target as Ozempic and Wegovy. Activating it reduces appetite and slows how quickly the stomach empties, so people eat less without deliberately restricting.
In the trials behind its approval, adults with obesity and without diabetes lost 11.1% of body weight on average over 72 weeks at the maximum dose, against 2.1% on placebo. Nearly three quarters lost at least 5% of their weight, and about one in five lost at least 20%.
That is real, and it is also the smallest figure among the approved weight-loss drugs: semaglutide reaches about 14.9% and tirzepatide about 20.9%. Foundayo trades some efficacy for the tablet. The dose-by-dose figures are in Foundayo weight loss.
How you take it
One tablet a day, with or without food, swallowed whole. The dose starts at 0.8 mg and steps up no sooner than every 30 days through 2.5, 5.5, 9 and 14.5 mg to a maximum of 17.2 mg — so reaching the full dose takes about five months. Full details in how to take Foundayo.
What it feels like
Mostly digestive, mostly early. At the maximum dose the label reports nausea in 35% of patients, diarrhoea in 25%, vomiting in 24% and constipation in 24%. Most people who get these describe them as mild, and they are worst while the dose is climbing.
Being a tablet does not make it gentler than an injection, and it does not make it harsher either — Foundayo sits between injected tirzepatide at 28% nausea and injected semaglutide at 44%. The full table by dose is in Foundayo side effects.
Who it is not for
- Anyone with a personal or family history of medullary thyroid carcinoma, or MEN 2.
- Anyone who has had a serious allergic reaction to orforglipron.
- It is not recommended in severe liver impairment, and should be stopped when a pregnancy is recognised.
- It is not intended to be combined with another GLP-1 medication.
Where to go from here
The full Foundayo guide covers the evidence, dosing and cost in one place. If you are weighing it against an injection, the comparisons are Foundayo vs Wegovy and Foundayo vs Zepbound. For what it costs and what the savings card actually does, see Foundayo cost and savings card.
If you are deciding
The two questions people ask next are what it costs and how it compares. Foundayo cost works through a full year rather than a monthly price, and Foundayo insurance coverage covers whether a plan will pay for any of it.
Scientific References
1 sourceReferences open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What is Foundayo?
A once-daily tablet approved by the FDA in April 2026 for weight management in adults with obesity, or with overweight plus a weight-related condition. Its active ingredient is orforglipron, and it works by activating the GLP-1 receptor to reduce appetite — the same target as Ozempic and Wegovy, in a form you swallow.
Is Foundayo the same as orforglipron?
Yes. Orforglipron is the drug's nonproprietary name and Foundayo is Eli Lilly's brand name for it. The same relationship as semaglutide and Ozempic, or tirzepatide and Zepbound.
Why can Foundayo be a pill when Ozempic is an injection?
Because it is chemically a different kind of drug. Semaglutide and tirzepatide are peptides — amino acid chains that the digestive system breaks down, which is why they are injected. Orforglipron is a conventional small molecule, synthesised in a chemistry plant, and it survives the stomach without special formulation. That also makes it cheaper to manufacture.
How much weight can you lose on Foundayo?
In the trial behind its approval, adults with obesity and without diabetes lost 11.1% of body weight on average over 72 weeks at the maximum 17.2 mg dose, against 2.1% on placebo. Around 71.5% lost at least 5% of their weight and 18.4% lost at least 20%. It is the lowest figure among approved weight-loss drugs, below semaglutide's roughly 14.9% and tirzepatide's roughly 20.9%.
Is Foundayo approved by the FDA?
Yes, in April 2026, for weight reduction and long-term weight maintenance in adults with obesity or with overweight plus at least one weight-related condition. It has a full prescribing label, which is what separates it from investigational molecules like retatrutide that are still in trials.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.